An insect growth inhibitor--lufenuron--enhances albendazole activity against hydatid cyst

Vet Parasitol. 2011 Sep 27;181(2-4):341-4. doi: 10.1016/j.vetpar.2011.04.011. Epub 2011 Apr 15.

Abstract

The aim of this work was to evaluate the potential of lufenuron, a benzylphenylurea with ability to interfere with the formation of insect exoskeleton, as a therapeutic drug for larval echinococcosis (hydatid disease). For this purpose lufenuron, alone or in combination with albendazole, was administered to CD1 mice bearing Echinococcus granulosus hydatid cysts in the peritoneal cavity. Neither of the drugs alone was able to exert parasiticidal effects. However, in combination with albendazole, lufenuron reduced the growth of cysts (30-40% in cyst diameter respect to control, p<0.05). This effect was associated with ultrastructural alterations of the hydatid cyst wall and a reduction of the content of myo-inositol-hexakisphosphate, the major component of the electron dense granules of the laminated layer. Overall, this work provides evidence that lufenuron could represent a useful compound for the use in chemotherapy against larval echinococcosis, by enhancing albendazole parasiticidal activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albendazole / administration & dosage
  • Albendazole / therapeutic use*
  • Animals
  • Anthelmintics / administration & dosage
  • Anthelmintics / therapeutic use*
  • Benzamides / administration & dosage
  • Benzamides / therapeutic use*
  • Drug Synergism
  • Drug Therapy, Combination
  • Echinococcosis / drug therapy*
  • Mice

Substances

  • Anthelmintics
  • Benzamides
  • fluphenacur
  • Albendazole